Astarabine

Drug Profile

Astarabine

Alternative Names: Ara-C asparagine conjugate; Asparagine ara-C conjugate; Asparagine cytarabine conjugate; Astarabine; BSR-236; Cytarabine asparagine conjugate

Latest Information Update: 18 Feb 2017

Price : $50

At a glance

  • Originator BioSight
  • Class Amino acids; Antineoplastics; Arabinonucleosides; Drug conjugates; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Preclinical Chronic myeloid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Dec 2016 Interim adverse events and efficacy data from a phase I/II trial in Acute myeloid leukaemia and Acute lymphocytic leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 17 May 2016 BioSight plans a phase IIb study in Acute myeloid leukaemia in USA Europe and Israel
  • 19 Apr 2016 BioSight completes enrolment in its phase I/II trial for Acute myeloid leukemia and Acute lymphoblastic leukemia in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top